Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
MWN-AI** Summary
Simulations Plus, Inc. (Nasdaq: SLP), a prominent provider of simulation and analytics software for the biopharmaceutical industry, disclosed its financial results for the third quarter of fiscal 2025, which concluded on May 31, 2025. The company reported total revenues of $20.4 million, marking a 10% increase compared to the same period last year. Software revenues accounted for 62% of total revenue at $12.6 million, a 6% rise, while service revenues grew by 17% to $7.7 million.
Despite the revenue growth, Simulations Plus disclosed a significant net loss of $67.3 million, attributed to a non-cash impairment charge of $77.2 million. This loss translates into a diluted loss per share of $3.35, contrasting sharply with a net income of $3.1 million and diluted earnings per share of $0.15 from the prior year.
Adjusted figures showed a more favorable scenario, with adjusted net income rising to $9.0 million and adjusted diluted EPS at $0.45, compared to $5.6 million and $0.27 respectively for the prior year.
For the nine-month period ending May 31, 2025, total revenues climbed to $61.7 million, reflecting a year-over-year increase of 20%. The company updated its revenue guidance for fiscal year 2025 to a range of $76 million to $80 million, with expected adjusted diluted EPS between $0.93 and $1.06.
CEO Shawn O’Connor noted strong demand and a healthy sales pipeline, though acknowledged project delays and cautious client spending impacted their performance. The firm is also implementing strategic organizational changes to enhance efficiency and is rolling out new AI-driven product initiatives to strengthen its market position. A conference call is scheduled for further discussion, providing insights into their performance and forward-looking strategies.
MWN-AI** Analysis
Simulations Plus, Inc. (SLP) has reported its third quarter fiscal 2025 financial results, showcasing a mixed bag of performance metrics. Notably, total revenues increased by 10% year-over-year to $20.4 million, buoyed by a 17% surge in services revenue and steady software revenue growth. However, the company suffered a substantial net loss of $67.3 million due to a one-time non-cash impairment charge of $77.2 million, overshadowing its operational positives.
In evaluating the updated full-year revenue guidance of $76 to $80 million, analysts should pay close attention to the shifts in the revenue mix—software is projected to comprise 55-60% of total sales. This indicates a desire to pivot towards higher-margin software solutions, which historically have yielded better gross margins (64% in Q3). The adjusted diluted EPS of $0.93 to $1.06 reflects underlying profitability improvement, despite the non-GAAP metrics showing a favorable trajectory.
However, investors should remain cautiously optimistic; the decline in QSP/QST biosimulation software sales and project delays signal potential volatility. Furthermore, the strategic transition to a functionally-driven model may take time to stabilize and materialize expected efficiencies. The company’s commitment to AI-driven innovations is promising but needs tangible results to assure stakeholders of sustained competitive advantage.
In summary, while Simulations Plus exhibits growth in top-line revenue and evolving operational strategies, the significant net loss and restructuring charges are concerning. Investors should weigh these risks against the company's growth potential in the biopharma industry. A gradual accumulation may be advisable, watching for signs of effective execution in the company’s operational restructuring and AI initiatives that could enhance future profitability.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its third quarter fiscal 2025, ended May 31, 2025.
Third Quarter 2025 Financial Highlights (as compared to third quarter 2024)
- Total revenue increased 10% to $20.4 million
- Software revenue increased 6% to $12.6 million, representing 62% of total revenue
- Services revenue increased 17% to $7.7 million, representing 38% of total revenue
- Gross profit was $13.0 million; gross margin was 64%
- Net loss of $67.3 million and diluted loss per share of $3.35, reflecting a non-cash impairment charge of $77.2 million, compared to net income of $3.1 million and diluted EPS of $0.15
- Adjusted EBITDA of $7.4 million, representing 37% of total revenue, compared to $5.6 million, representing 30% of total revenue
- Adjusted net income of $9.0 million and adjusted diluted EPS of $0.45 compared to adjusted net income of $5.6 million and adjusted diluted EPS of $0.27
Nine Months 2025 Financial Highlights (as compared to nine months 2024)
- Total revenue increased 20% to $61.7 million
- Software revenue increased 18% to $36.8 million, representing 60% of total revenue
- Services revenue increased 23% to $24.9 million, representing 40% of total revenue
- Gross profit was $36.4 million; gross margin was 59%
- Net loss of $64.0 million and diluted loss per share of $3.19, reflecting a non-cash impairment charge of $77.2 million versus net income of $9.1 million and diluted EPS of $0.45
- Adjusted EBITDA of $18.5 million, representing 30% of total revenue, compared to $16.1 million, representing 31% of total revenue
- Adjusted net income of $18.7 million and adjusted diluted EPS of $0.93, compared to adjusted net income of $15.7 million and adjusted diluted EPS of $0.77
Management Commentary
“In the third quarter, our revenue grew by 10% in line with our preliminary revenue,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus. “Our software revenue continued to perform well, increasing 6%, mainly driven by our ADMET Predictor® software and modest growth in our GastroPlus® and MonolixSuite TM software, partially offset by a decline in our QSP/QST biosimulations software.
“Services revenue for the third fiscal quarter grew by 17%, primarily driven by solid performance in our Medical Communications services. However, we experienced a decline in other service areas, largely due to cautious spending behavior, project delays and a cancellation from our BioPharma clients. While the sales pipeline remains robust with healthy client interest, the pace of contractual commitments slowed, impacting third quarter 2025 bookings.
“We also recognized a one-time non-cash impairment charge of $77.2 million this quarter. This charge was based on a valuation assessment we made and aligns the book value of our assets to their current market value. It also reflects our commitment to transparency as we streamline our operating structure for greater efficiency and impact.
“During the quarter, we also implemented a strategic reorganization, transitioning from a business unit structure to a functionally-driven operating model. This marked the final phase of a multi-year transformation to streamline operations, unlock synergies across teams, and concentrate our resources on the most promising growth opportunities. Additionally, we identified efficiencies in our cost structure that resulted in right-sizing our staffing levels and better aligning our services capacity to match current client needs.
“Despite the current macroeconomic environment, our team remains focused on innovation, and we are rolling out a series of new AI-driven initiatives across our product lines. By applying advanced technologies like AI to drive innovation and growth, we believe these new and eagerly anticipated solutions will expand our value proposition and give us a distinct competitive advantage in the biosimulation market. This strategy not only enriches our product ecosystem but also positions Simulations Plus for sustained growth and further solidifies our leadership in model-informed drug development solutions,” concluded O’Connor.
Fiscal 2025 Guidance
Simulations Plus is updating its full fiscal year 2025 guidance as follows:
Fiscal 2025 Guidance
Fiscal 2025 Guidance | ||
Revenue | $76M - $80M | |
Revenue growth | 9 - 14% | |
Software mix | 55 - 60% | |
Adjusted EBITDA margin | 23 - 27% | |
Adjusted diluted EPS | $0.93 - $1.06 |
Webcast and Conference Call Details
Shawn O’Connor, Chief Executive Officer, and Will Frederick, Chief Financial Officer, will host a conference call and webcast today at 5:00 p.m. Eastern Time to discuss the details of Simulations Plus’ performance for the quarter and certain forward-looking information. The call may be accessed by registering here or by calling 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on the investor relations page of the Simulations Plus website https://www.simulations-plus.com/investorscorporate-profile/corporate-profile/ where it will also be available for replay approximately one hour following the call.
Non-GAAP Financial Measures
This press release contains “non-GAAP financial measures,” which are measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”).
A further explanation and reconciliation of these non-GAAP financial measures is included below and in the financial tables in this release.
The Company believes that the non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods. The Company’s management uses non-GAAP financial measures to, among other things, evaluate its ongoing operations in relation to historical results, for internal planning and forecasting purposes and in the calculation of performance-based compensation. Adjusted EBITDA and Adjusted Diluted EPS represent measures that we believe are customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that these measures are useful in evaluating our core operating results. However, Adjusted EBITDA and Adjusted Diluted EPS are not measures of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income, operating income, or diluted EPS as indicators of our operating performance or to net cash provided by operating activities as a measure of our liquidity. We believe the Company’s Adjusted EBITDA and Adjusted Diluted EPS measures provide information that is directly comparable to that provided by other peer companies in our industry, but other companies may calculate non-GAAP financial results differently, particularly related to nonrecurring, unusual items.
Please note that the Company has not reconciled the adjusted EBITDA or adjusted diluted earnings per share forward-looking guidance included in this press release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.
Adjusted EBITDA
Adjusted EBITDA represents net income excluding the effect of interest expense (income), provision (benefit) for income taxes, amortization expense, intangible asset amortization, equity-based compensation expense, loss (gain) on currency exchange, goodwill impairment, change in fair value of contingent consideration, reorganization expense, acquisition and integration expense and other items not indicative of our ongoing operating performance.
Adjusted Net Income and Adjusted Diluted EPS
Adjusted net income and adjusted diluted earnings per share exclude the effect of amortization expense, equity-based compensation expense, loss (gain) on currency exchange, goodwill impairment, change in fair value of contingent consideration, reorganization expense, acquisition and integration expense and other items not indicative of our ongoing operating performance as well as the income tax provision adjustment for such charges.
The Company excludes the above items because they are outside of the Company’s normal operations and/or, in certain cases, are difficult to forecast accurately for future.
With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com . Follow us on LinkedIn | X | YouTube .
Environmental, Social, and Governance
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update .
Forward-Looking Statements
Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will”, “can”, “believe”, “expect,” “anticipate” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new internal operational structure, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
SIMULATIONS PLUS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (Unaudited) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
(in thousands, except per common share amounts) | May 31, 2025 | May 31, 2024 | May 31, 2025 | May 31, 2024 | ||||||||||||
Revenues | ||||||||||||||||
Software | $ | 12,615 | $ | 11,908 | $ | 36,814 | $ | 31,111 | ||||||||
Services | 7,748 | 6,636 | 24,905 | 20,238 | ||||||||||||
Total revenues | 20,363 | 18,544 | 61,719 | 51,349 | ||||||||||||
Cost of revenues | ||||||||||||||||
Software | 2,540 | 1,400 | 7,765 | 3,739 | ||||||||||||
Services | 4,791 | 3,887 | 17,577 | 11,284 | ||||||||||||
Total cost of revenues | 7,331 | 5,287 | 25,342 | 15,023 | ||||||||||||
Gross profit | 13,032 | 13,257 | 36,377 | 36,326 | ||||||||||||
Operating expenses | ||||||||||||||||
Research and development | 1,216 | 1,300 | 5,207 | 3,829 | ||||||||||||
Sales and marketing | 2,680 | 2,399 | 9,248 | 6,337 | ||||||||||||
General and administrative | 6,141 | 7,678 | 16,089 | 18,878 | ||||||||||||
Impairments | 77,221 | — | 77,221 | — | ||||||||||||
Total operating expenses | 87,258 | 11,377 | 107,765 | 29,044 | ||||||||||||
(Loss) income from operations | (74,226 | ) | 1,880 | (71,388 | ) | 7,282 | ||||||||||
Other income, net | 182 | 2,010 | 1,122 | 4,266 | ||||||||||||
(Loss) income before income taxes | (74,044 | ) | 3,890 | (70,266 | ) | 11,548 | ||||||||||
Income tax benefit (expense) | 6,727 | (753 | ) | 6,229 | (2,437 | ) | ||||||||||
Net (loss) income | $ | (67,317 | ) | $ | 3,137 | $ | (64,037 | ) | $ | 9,111 | ||||||
(Loss) Earnings per share | ||||||||||||||||
Basic | $ | (3.35 | ) | $ | 0.16 | $ | (3.19 | ) | $ | 0.46 | ||||||
Diluted | $ | (3.35 | ) | $ | 0.15 | $ | (3.19 | ) | $ | 0.45 | ||||||
Weighted-average common shares outstanding | ||||||||||||||||
Basic | 20,113 | 19,995 | 20,092 | 19,972 | ||||||||||||
Diluted | 20,113 | 20,433 | 20,092 | 20,324 | ||||||||||||
Other comprehensive (loss) income, net of tax | ||||||||||||||||
Foreign currency translation adjustments | 41 | (56 | ) | (27 | ) | (125 | ) | |||||||||
Unrealized gains (losses) on available-for-sale securities | — | (39 | ) | 4 | (39 | ) | ||||||||||
Comprehensive (loss) income | $ | (67,276 | ) | $ | 3,042 | $ | (64,060 | ) | $ | 8,947 |
SIMULATIONS PLUS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
(Unaudited) | ||||||||
(in thousands, except share and per share amounts) | May 31, | August 31, | ||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 26,950 | $ | 10,311 | ||||
Accounts receivable, net of allowance for credit losses of $255 and $149 | 14,780 | 9,136 | ||||||
Prepaid income taxes | 954 | 2,197 | ||||||
Prepaid expenses and other current assets | 7,591 | 7,753 | ||||||
Short-term investments | 1,500 | 9,944 | ||||||
Total current assets | 51,775 | 39,341 | ||||||
Long-term assets | ||||||||
Capitalized computer software development costs, net of accumulated amortization of $21,096 and $18,727 | 11,301 | 12,499 | ||||||
Property and equipment, net | 681 | 812 | ||||||
Operating lease right-of-use assets | 425 | 1,027 | ||||||
Intellectual property, net of accumulated amortization of $8,754 and $5,490 | 6,464 | 23,130 | ||||||
Other intangible assets, net of accumulated amortization of $4,146 and $3,177 | 12,368 | 23,210 | ||||||
Goodwill | 43,487 | 96,078 | ||||||
Deferred tax assets, net | 7,429 | — | ||||||
Other assets | 430 | 542 | ||||||
Total assets | $ | 134,360 | $ | 196,639 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 1,663 | $ | 602 | ||||
Accrued compensation | 1,656 | 4,513 | ||||||
Accrued expenses | 2,199 | 2,043 | ||||||
Contracts payable - current portion | — | 2,440 | ||||||
Operating lease liability - current portion | 269 | 475 | ||||||
Deferred revenue | 4,344 | 1,996 | ||||||
Total current liabilities | 10,131 | 12,069 | ||||||
Long-term liabilities | ||||||||
Deferred tax liabilities, net | — | 1,608 | ||||||
Operating lease liability - net of current portion | 450 | 531 | ||||||
Total liabilities | 10,581 | 14,208 | ||||||
Commitments and contingencies - Note 4 | ||||||||
Shareholders' equity | ||||||||
Preferred stock, $0.001 par value — 10,000,000 shares authorized; no shares issued and outstanding | $ | — | $ | — | ||||
Common stock, $0.001 par value; 50,000,000 shares authorized, 20,116,181 and 20,051,134 shares issued and outstanding as of May 31, 2025 and August 31, 2024 | 20,116 | 20,051 | ||||||
Additional paid-in capital | 137,620 | 132,277 | ||||||
(Accumulated deficit) retained earnings | (33,683 | ) | 30,354 | |||||
Accumulated other comprehensive loss | (274 | ) | (251 | ) | ||||
Total shareholders' equity | 123,779 | 182,431 | ||||||
Total liabilities and shareholders' equity | $ | 134,360 | 196,639 |
SIMULATIONS PLUS, INC. Trended Financial Information (1) (Unaudited) | ||||||||||||||||||||||||||||||||||||
(in millions except earnings per share amounts) | ||||||||||||||||||||||||||||||||||||
FY24 | FY25 | FY24 | FY25 | |||||||||||||||||||||||||||||||||
Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Full Year | YTD | ||||||||||||||||||||||||||||
Revenue | ||||||||||||||||||||||||||||||||||||
Software | $ | 7.589 | $ | 11.614 | $ | 11.908 | $ | 9.913 | $ | 10.715 | $ | 13.484 | $ | 12.615 | $ | 41.024 | $ | 36.814 | ||||||||||||||||||
Services | $ | 6.911 | $ | 6.691 | $ | 6.636 | $ | 8.751 | $ | 8.209 | $ | 8.948 | $ | 7.748 | $ | 28.989 | $ | 24.905 | ||||||||||||||||||
Total | $ | 14.500 | $ | 18.305 | $ | 18.544 | $ | 18.664 | $ | 18.924 | $ | 22.432 | $ | 20.363 | $ | 70.013 | $ | 61.719 | ||||||||||||||||||
Gross Margin | ||||||||||||||||||||||||||||||||||||
Software | 86.9 | % | 88.4 | % | 88.2 | % | 72.4 | % | 75.4 | % | 80.8 | % | 79.9 | % | 84.2 | % | 78.9 | % | ||||||||||||||||||
Services | 47.0 | % | 44.2 | % | 41.4 | % | -4.0 | % | 26.1 | % | 24.9 | % | 38.2 | % | 29.7 | % | 29.4 | % | ||||||||||||||||||
Total | 67.9 | % | 72.2 | % | 71.5 | % | 36.6 | % | 54.0 | % | 58.5 | % | 64.0 | % | 61.6 | % | 58.9 | % | ||||||||||||||||||
Income from operations | $ | 0.960 | $ | 4.442 | $ | 1.880 | $ | (1.151 | ) | $ | 0.126 | $ | 2.712 | $ | (74.226 | ) | $ | 6.131 | $ | (71.388 | ) | |||||||||||||||
Operating Margin | 6.6 | % | 24.3 | % | 10.1 | % | -6.2 | % | 0.7 | % | 12.1 | % | -364.5 | % | 8.8 | % | -115.7 | % | ||||||||||||||||||
Net Income | $ | 1.945 | $ | 4.029 | $ | 3.137 | $ | 0.843 | $ | 0.206 | $ | 3.074 | $ | (67.317 | ) | $ | 9.954 | $ | (64.037 | ) | ||||||||||||||||
Diluted Earnings Per Share | $ | 0.10 | $ | 0.20 | $ | 0.15 | $ | 0.04 | $ | 0.01 | $ | 0.15 | $ | (3.35 | ) | $ | 0.49 | $ | (3.19 | ) | ||||||||||||||||
Adjusted EBITDA | $ | 3.388 | $ | 7.135 | $ | 5.586 | $ | 4.148 | $ | 4.493 | $ | 6.578 | $ | 7.437 | $ | 20.257 | $ | 18.508 | ||||||||||||||||||
Adjusted Diluted EPS | $ | 0.18 | $ | 0.32 | $ | 0.27 | $ | 0.18 | $ | 0.17 | $ | 0.31 | $ | 0.45 | $ | 0.95 | $ | 0.93 | ||||||||||||||||||
Cash Flow from Operations | $ | 0.162 | $ | 5.810 | $ | 5.700 | $ | 1.600 | $ | (1.274 | ) | $ | 5.669 | $ | 8.144 | $ | 13.320 | $ | 12.539 | |||||||||||||||||
Revenue Breakdown by Region | ||||||||||||||||||||||||||||||||||||
Americas | $ | 10.891 | $ | 12.461 | $ | 12.428 | $ | 14.693 | $ | 14.469 | $ | 16.112 | $ | 14.544 | $ | 50.473 | $ | 45.125 | ||||||||||||||||||
EMEA | 2.302 | 4.665 | 4.513 | 2.592 | 2.720 | 4.806 | 3.698 | 14.072 | 11.224 | |||||||||||||||||||||||||||
Asia Pacific | 1.307 | 1.179 | 1.603 | 1.379 | 1.735 | 1.514 | 2.121 | 5.468 | 5.370 | |||||||||||||||||||||||||||
Total | $ | 14.500 | $ | 18.305 | $ | 18.544 | $ | 18.664 | $ | 18.924 | $ | 22.432 | $ | 20.363 | $ | 70.013 | $ | 61.719 | ||||||||||||||||||
Software Performance Metrics | ||||||||||||||||||||||||||||||||||||
Avg. Revenue per Customer (in thousands) | ||||||||||||||||||||||||||||||||||||
Commercial | $ | 79.0 | $ | 113.0 | $ | 97.0 | $ | 89.0 | $ | 94.0 | $ | 124.0 | $ | 96.0 | ||||||||||||||||||||||
Services Performance Metrics | ||||||||||||||||||||||||||||||||||||
Backlog (in millions) | $ | 18.910 | $ | 18.041 | $ | 19.602 | $ | 14.091 | $ | 17.254 | $ | 20.379 | $ | 20.700 |
(1) | Numbers may not foot due to rounding |
SIMULATIONS PLUS, INC. Reconciliation of Adjusted EBITDA to Net Income (1) (Unaudited) | ||||||||||||||||||||||||||||||||||||
(in millions) | ||||||||||||||||||||||||||||||||||||
FY 2024 | FY25 | FY24 | FY25 | |||||||||||||||||||||||||||||||||
Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Full Year | YTD | ||||||||||||||||||||||||||||
Net Income | $ | 1.945 | $ | 4.029 | $ | 3.137 | $ | 0.843 | $ | 0.206 | $ | 3.074 | $ | (67.317 | ) | $ | 9.954 | $ | (64.037 | ) | ||||||||||||||||
Excluding: | ||||||||||||||||||||||||||||||||||||
Interest income and expense, net | (1.292 | ) | (1.348 | ) | (1.522 | ) | (0.213 | ) | (0.159 | ) | (0.154 | ) | (0.170 | ) | (4.375 | ) | (0.483 | ) | ||||||||||||||||||
Provision for income taxes | 0.461 | 1.223 | 0.753 | 0.020 | 0.064 | 0.434 | (6.727 | ) | 2.457 | (6.229 | ) | |||||||||||||||||||||||||
Depreciation and amortization | 1.091 | 1.105 | 1.263 | 2.206 | 2.265 | 2.274 | 2.318 | 5.665 | 6.857 | |||||||||||||||||||||||||||
Stock-based compensation | 1.303 | 1.585 | 1.665 | 1.387 | 1.589 | 1.557 | 1.279 | 5.940 | 4.425 | |||||||||||||||||||||||||||
(Gain) loss on currency exchange | (0.044 | ) | 0.098 | (0.009 | ) | (0.431 | ) | 0.015 | (0.002 | ) | (0.035 | ) | (0.386 | ) | (0.022 | ) | ||||||||||||||||||||
Impairments | — | — | — | — | — | — | 77.221 | — | 77.221 | |||||||||||||||||||||||||||
(Loss) income from disposal of fixed assets | — | — | — | — | — | — | 0.023 | — | 0.023 | |||||||||||||||||||||||||||
Change in value of contingent consideration | (0.110 | ) | 0.440 | (0.599 | ) | (1.370 | ) | — | (0.640 | ) | — | (1.639 | ) | (0.640 | ) | |||||||||||||||||||||
Reorganization expense | — | — | — | — | 0.258 | 0.157 | 0.845 | — | 1.260 | |||||||||||||||||||||||||||
Mergers & Acquisitions expense | 0.034 | 0.003 | 0.898 | 1.706 | 0.255 | (0.122 | ) | — | 2.641 | 0.133 | ||||||||||||||||||||||||||
Adjusted EBITDA | $ | 3.388 | $ | 7.135 | $ | 5.586 | $ | 4.148 | $ | 4.493 | $ | 6.578 | $ | 7.437 | $ | 20.257 | $ | 18.508 |
(1) | Numbers may not foot due to rounding |
SIMULATIONS PLUS, INC. Reconciliation of Adjusted Diluted EPS to Diluted EPS (1) (Unaudited) | ||||||||||||||||||||||||||||||||||||
(in millions, except Diluted EPS and Adjusted Diluted EPS) | ||||||||||||||||||||||||||||||||||||
FY 2024 | FY25 | FY24 | FY25 | |||||||||||||||||||||||||||||||||
Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Full Year | YTD | ||||||||||||||||||||||||||||
Net (loss) Income (GAAP) | $ | 1.945 | $ | 4.029 | $ | 3.137 | $ | 0.843 | $ | 0.206 | $ | 3.074 | $ | (67.317 | ) | $ | 9.954 | $ | (64.037 | ) | ||||||||||||||||
Excluding: | ||||||||||||||||||||||||||||||||||||
Amortization | 0.991 | 0.991 | 1.122 | 2.059 | 2.130 | 2.130 | 2.165 | 5.163 | 6.425 | |||||||||||||||||||||||||||
Stock-based compensation | 1.303 | 1.585 | 1.665 | 1.387 | 1.589 | 1.557 | 1.279 | 5.940 | 4.425 | |||||||||||||||||||||||||||
(Gain) loss on currency exchange | (0.044 | ) | 0.098 | (0.009 | ) | (0.431 | ) | 0.015 | (0.002 | ) | (0.035 | ) | (0.386 | ) | (0.022 | ) | ||||||||||||||||||||
Mergers & Acquisitions expense | 0.034 | 0.003 | 0.898 | 1.706 | 0.255 | (0.122 | ) | — | 2.641 | 0.133 | ||||||||||||||||||||||||||
Change in value of contingent consideration | (0.110 | ) | 0.440 | (0.599 | ) | (1.370 | ) | — | (0.640 | ) | — | (1.639 | ) | (0.640 | ) | |||||||||||||||||||||
Reorganization expense | — | — | — | — | 0.258 | 0.157 | 0.845 | — | 1.260 | |||||||||||||||||||||||||||
Impairments | — | — | — | — | — | — | 77.221 | — | 77.221 | |||||||||||||||||||||||||||
(Loss) income from disposal of fixed assets | — | — | — | — | — | — | 0.023 | — | 0.023 | |||||||||||||||||||||||||||
Tax effect on above adjustments | (0.417 | ) | (0.746 | ) | (0.603 | ) | (0.554 | ) | (1.007 | ) | 0.041 | (5.153 | ) | (2.320 | ) | (6.119 | ) | |||||||||||||||||||
Adjusted Net income (Non-GAAP) | $ | 3.702 | $ | 6.400 | $ | 5.611 | $ | 3.640 | $ | 3.446 | $ | 6.195 | $ | 9.028 | $ | 19.353 | $ | 18.669 | ||||||||||||||||||
Weighted-avg. common shares outstanding: | ||||||||||||||||||||||||||||||||||||
Diluted | 20,279 | 20,315 | 20,433 | 20,338 | 20,266 | 20,277 | 20,113 | 20,301 | 20,092 | |||||||||||||||||||||||||||
Diluted EPS (GAAP) | $ | 0.10 | $ | 0.20 | $ | 0.15 | $ | 0.04 | $ | 0.01 | $ | 0.15 | $ | (3.35 | ) | $ | 0.49 | $ | (3.19 | ) | ||||||||||||||||
Adjusted Diluted EPS (Non-GAAP) | $ | 0.18 | $ | 0.32 | $ | 0.27 | $ | 0.18 | $ | 0.17 | $ | 0.31 | $ | 0.45 | $ | 0.95 | $ | 0.93 |
(1) | Numbers may not foot due to rounding |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250714949901/en/
Investor Relations Contact :
Lisa Fortuna
Financial Profiles
310-622-8251
slp@finprofiles.com
FAQ**
How does the recent non-cash impairment charge of $77.2 million in Simulations Plus Inc. SLP impact future earnings and the company’s overall financial strategy?
What specific AI-driven initiatives is Simulations Plus Inc. SLP planning to implement to enhance its product offerings and maintain its competitive edge in the biosimulation market?
Given the decline in QSP/QST biosimulations software revenue, what steps is Simulations Plus Inc. SLP taking to address this issue and improve its product portfolio?
How does the updated full-year revenue guidance of $76-$80 million for Simulations Plus Inc. SLP reflect the company's growth potential and market conditions moving forward?
**MWN-AI FAQ is based on asking OpenAI questions about Simulations Plus Inc. (NASDAQ: SLP).
NASDAQ: SLP
SLP Trading
0.82% G/L:
$12.32 Last:
44,832 Volume:
$12.36 Open:
